ROCKWELL MEDICAL, INC.
For the period ended Apr 30, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 30, 2026 · Filed Apr 30, 2026
Use the contents to explore the available documents and sections.
Contents
Summary Compensation Table
| Name and Principal Position | Year | Salary($) | Bonus ($) | Stock Awards ($)(a) | Option Awards ($)(a) | Non-Equity Incentive Plan Compensation ($)(b) | All Other Compensation ($)(c) | Total ($) |
|---|---|---|---|---|---|---|---|---|
| Mark Strobeck, Ph.D. | 2025 | 566,500(d) | — | 612,040 | 249,732 | 453,200 | 14,000 | 1,895,472 |
| Chief Executive Officer | 2024 | 566,500(d) | — | 139,000 | 138,378 | 453,200(e) | 13,800 | 1,310,878 |
| Jesse Neri | 2025 | 309,000 | — | 208,650 | 158,109 | 139,050 | 14,000 | 828,809 |
| Chief Financial Officer | 2024 | 300,000(d) | — | 46,329 | 46,129 | 135,000 | 12,000 | 539,458 |
| Megan Timmins | 2025 | 412,000(d) | — | 208,650 | 158,109 | 185,400 | 14,000 | 978,159 |
| Chief Legal Officer and Secretary | 2024 | 412,000(d) | — | 69,500 | 69,189 | 185,400 | 13,800 | 749,889 |
(a)The amounts reported in this column represent grant date fair values of performance-based restricted stock unit and restricted stock unit grants computed in accordance with FASB ASC Topic 718 and stock option grants determined using the Black Scholes option pricing model, excluding any forfeiture reserves, in accordance with FASB ASC Topic 718. There is only a single possible payout under the performance-based restricted stock units. The assumptions used to determine fair value of the stock option grants for 2025 are:
| Options | Year Granted | Dividend Yield | Risk Free Rate | Volatility | Expected Term |
|---|---|---|---|---|---|
| Mark Strobeck | 2025 | 0.00% | 4.14% | 90.42% | 5.86 years |
| Jesse Neri | 2025 | 0.00% | 4.14% | 90.42% | 5.86 years |
| Megan Timmins | 2025 | 0.00% | 4.14% | 90.42% | 5.86 years |
(b)See “Annual Incentive Compensation” below for a description of the amounts included in this column.
(c)Represents matching contributions under our 401(k) plan.
(d)Dr. Strobeck, Mr. Neri and Ms. Timmins requested no base salary increase for 2024 to contribute to a larger pool for base salary increases for the Company’s other employees. Dr. Strobeck and Ms. Timmins requested no base salary increase for 2025 to contribute to a larger pool for base salary increases for the Company’s other employees.
(e)80% of Dr. Strobeck’s 2024 bonus ($362,560) was paid upon approval, and 20% of Dr. Strobeck’s bonus ($90,640) is payable on July 29, 2026 or on a change in control transaction (if earlier), in each case provided that Dr. Strobeck remains an employee of the Company until such payment date.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.